Cancer is the second leading cause of death among Native Americans, yet <1% of clinical trial participants identify as Native American, potentially leading to treatments that are less effective for Indigenous patients. A new study from OU Health Stephenson Cancer Center tested an in-person clinical trial education (CTE) program designed with input from an Indigenous community advisory board. Access insights from the study and review potential next steps in the #ACORI Research Review newsletter🔗 https://brnw.ch/21wRLuL. #HealthEquity #ClinicalTrials #NativeHealth #CancerResearch (fb)

Up to 50% of patients receiving cancer treatment experience dermatologic toxicities—adverse events (AEs) affecting the skin, hair, or nails that can interrupt or delay treatment. How can these AEs be recognized and managed effectively? 📘 Preventing and Managing Common Dermatologic Toxicities: A Guide for Clinicians offers: • Real-world examples of common dermatologic toxicities and associated therapies • Evidence-based prevention and management strategies • Educational tools for improving oncodermatology care coordination 👉Access ACCC’s guide and explore more resources at accc-cancer.org/dermatologic-toxicities Thank you to our partners: Skin of Color Society | Oncodermatology Society | Multinational Association of Supportive Care in Cancer (MASCC) #Oncodermatology #CancerCare #SupportiveCare #Oncology #ACCC • Beth Sandy, MSN, CRNP • Cynthia Ryan, PharmD, BCPS • Jae Jung, MD, PhD • Jesse Himer, MD, MS, FAAD • Matthew Manning, MD, FASTRO, FACC • Milan J. Anadkat, MD • Rajan Kulkarni, MD, PhD (fb)